Corporate Finance

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

HarbourVest's $4.75B fund signals a major trend: investors are bypassing old models for direct access to deals in AI and tech. What does this mean for you?

With a new name and $35M in fresh funding, Allotera Therapeutics is doubling down on a pivotal trial for Sofi-cel, a therapy aimed at solving a tough T-cell cancer.

As private equity faces a liquidity crunch, Patria Investments' oversubscribed secondary fund reveals a winning strategy: targeting smaller, overlooked deals.

Beyond software, a new breed of venture capital is funding America's industrial rebirth, pouring millions into AI, robotics, and the factories of the future.

Waste Pro's latest $150M bond deal isn't just about money; it's a look into the financial engine driving a private company's rapid southeastern expansion.

Amid a tough fundraising climate, Hamilton Lane's record fund close reveals a key strategy for 2026: the enduring power of the middle-market buyout.

Suominen's oversubscribed rights issue raises €28M, a strong investor endorsement for its ambitious 'Full Potential Program' aimed at a major overhaul.

Exact Imaging's U.S. expansion signals a major shift. With technology rivaling MRI, micro-ultrasound is poised to make precision diagnostics more accessible.

While many fintechs burn billions, Singapore’s Qashier hit profitability on a lean budget. We dissect how its unified platform cracked the fragmented SEA market.

With a new $155M fund, Larsen Jensen's firm is arming deep tech startups to win the next geopolitical race, blending military strategy with venture capital.

Almonty Industries' inclusion in the Russell 1000 is more than a stock market milestone. It validates a strategy built at the nexus of profit and geopolitics.

X Square Robot's $2.8B valuation, backed by China's four tech giants, signals a strategic shift from digital screens to intelligent, physical robots.

Biotech innovator Ernexa Therapeutics launches a new CEO platform, betting that open communication can help it solve cell therapy's biggest challenge: cost.

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

A fintech-bank alliance wins top honors by solving cross-border payment pains for SMEs, leveraging AI and strategic partnership to capture a massive market.

Stegra secures a pivotal €1.4B to build its green steel plant, backed by Sweden's Wallenberg dynasty. This isn't just funding; it's the forging of a new industrial network.

Amid a stock surge, Glass House Brands forces a warrant exercise, a strategic move to inject cash and clean its books for a potential major exchange listing.

Beyond the 3-for-1 split, Willis Lease Finance Corp's shareholder vote is a powerful endorsement of its strategy in a rebounding aviation services sector.

As it turns 50, Menlo Ventures bets a historic $3B on the AI gold rush. Is it the culmination of a visionary legacy or a symptom of market frenzy?